BioCardia, Inc. — Regulatory Filings 2025

Jul 15, 2025

CORRESP 1 filename1.htm bcda20250714_corresp.htm Generated by ThunderDome Portal - 7/14/2025 10:00:44 PM

BioCardia, Inc.

320 Soquel Way

Sunnyvale, California 94085

July 15, 2025

Via EDGAR

U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE

Washington, D.C. 20549-3561

Attn: Joshua Gorsky

Re: BioCardia, Inc. Registration Statement on Form S-3 Filed July 9, 2025 File No. 333-288592

Acceleration Request

Requested Date: July 17, 2025

Requested Time: 4:30 p.m. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCardia, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-288592) (the “Registration Statement”), be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff of the Securities and Exchange Commission.

The Company hereby authorizes Austin March of Wilson Sonsini Goodrich & Rosati, P.C., counsel for the Company, to make such request on the Company’s behalf.

The Company requests that it be notified of the effectiveness of the Registration Statement by contacting Austin March at (512) 338-5410 or amarch@wsgr.com.

Sincerely,
BIOCARDIA, INC.
By:	/s/ David McClung
	David McClung Chief Financial Officer

cc: Peter Altman, BioCardia, Inc.

Austin March, Esq., Wilson Sonsini Goodrich & Rosati, P.C.